20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Aktis Oncology, Inc. Common stock (AKTS) operates in the BIOTECHNOLOGY industry and is headquartered in Boston, United States with about 79 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, AKTS reported $6M in revenue and ($64M) in net income.
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers.
Interactive charts & full statements → Open the AKTS valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $10M | $6M | $1M | $27M | $0M | $15M | $2M | $1M | $1M | $0M | $0M | — |
| Gross Profit | $9M | $6M | $1M | ($3M) | — | ($4M) | ($1M) | $0M | $0M | $0M | $0M | — |
| Gross Margin % | 84.8% | 100.0% | 100.0% | -11.5% | — | -27.0% | -34.9% | 29.8% | 15.6% | -548.9% | 88.7% | — |
| Operating Income (EBIT) | ($87M) | ($75M) | ($52M) | ($35M) | ($20M) | ($61M) | ($32M) | ($28M) | ($22M) | ($10M) | ($5M) | ($1M) |
| Operating Margin % | -866.6% | -1149.5% | -3500.3% | -128.3% | — | -394.5% | -1789.8% | -1906.9% | -1844.4% | -58704.1% | -1842.0% | — |
| Net Income | ($73M) | ($64M) | ($44M) | ($29M) | ($18M) | ($59M) | ($41M) | ($31M) | ($22M) | ($9M) | ($5M) | ($1M) |
| Net Margin % | -727.0% | -980.9% | -2957.6% | -105.6% | — | -385.6% | -2283.1% | -2139.9% | -1799.8% | -53691.6% | -2121.5% | — |
| EBITDA | ($78M) | ($61M) | ($42M) | ($27M) | ($17M) | ($53M) | ($29M) | ($25M) | ($21M) | ($11M) | ($4M) | ($1M) |
| Earnings Per Share (EPS) | $-1.35 | $-1.21 | $-1.26 | $-0.82 | $-0.51 | $-1.10 | $-1.21 | $-1.12 | $-1.04 | $-0.54 | $-0.40 | $-0.10 |
| Shares Outstanding (M) | 55M | 53M | 35M | 35M | 35M | 54M | 34M | 28M | 21M | 17M | 13M | 13M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $3M | $3M | $2M | $2M | $2M | $1M | $1M | $9M |
| Gross Profit | $3M | $3M | $2M | $2M | — | — | $1M | $4M |
| Gross Margin % | 74.0% | 79.8% | 100.0% | 100.0% | — | — | 100.0% | 47.7% |
| Operating Income (EBIT) | ($29M) | ($23M) | ($17M) | ($18M) | ($21M) | ($18M) | ($16M) | ($5M) |
| Operating Margin % | -854.0% | -703.6% | -929.1% | -1152.8% | -1309.4% | -1253.8% | -1675.8% | -59.1% |
| Net Income | ($24M) | ($18M) | ($15M) | ($16M) | ($18M) | ($15M) | ($12M) | ($6M) |
| Net Margin % | -713.5% | -567.9% | -809.5% | -983.7% | -1129.0% | -1035.6% | -1292.2% | -71.1% |
| EBITDA | ($28M) | ($18M) | ($14M) | ($18M) | — | — | ($12M) | ($4M) |
| Earnings Per Share (EPS) | $-0.44 | $-0.33 | $-0.28 | $-0.30 | — | — | $-0.23 | $-0.04 |
| Shares Outstanding (M) | 55M | 55M | 53M | 53M | — | — | 53M | 154M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($75M) | ($64M) | $15M | ($30M) | ($18M) | ($45M) | ($21M) | ($18M) | ($14M) | ($6M) | ($1M) | ($1M) |
| Capital Expenditures (CapEx) | $9M | $10M | $3M | $4M | $2M | $28M | $10M | $5M | $7M | $2M | $0M | $0M |
| Free Cash Flow (FCF) | ($85M) | ($74M) | $12M | ($34M) | ($20M) | ($73M) | ($31M) | ($23M) | ($21M) | ($7M) | ($1M) | ($1M) |
| FCF Margin % | -840.6% | -1134.5% | 800.3% | -124.5% | — | -475.0% | -1746.2% | -1565.6% | -1756.4% | -42645.6% | -450.3% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($21M) | ($24M) | ($15M) | ($15M) | ($16M) | ($17M) | ($13M) | ($12M) |
| Capital Expenditures (CapEx) | $1M | $2M | $4M | $2M | $2M | $2M | $2M | $0M |
| Free Cash Flow (FCF) | ($22M) | ($26M) | ($19M) | ($17M) | ($18M) | ($19M) | ($15M) | ($12M) |
| FCF Margin % | -645.7% | -808.7% | -1037.2% | -1090.9% | -1106.5% | -1339.0% | -1610.7% | -136.6% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $558M | $265M | $326M | $122M | $138M | $161M | $71M | $48M | $29M | $18M | $5M | $5M | $0M |
| Cash & Cash Equivalents | $82M | $38M | $37M | $30M | $129M | $80M | $44M | $30M | $15M | $10M | $4M | $4M | $0M |
| Total Liabilities | $73M | $411M | $414M | $169M | $158M | $58M | $30M | $22M | $15M | $3M | $2M | $0M | $0M |
| Total Debt (Short + Long-Term) | $1M | $1M | $1M | $2M | $1M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Total Shareholders' Equity | $485M | ($146M) | ($88M) | ($46M) | ($19M) | $103M | $41M | $26M | $14M | $15M | $3M | $4M | $0M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AKTS viewer.
About TickerBase · Data methodology & sources · Privacy · Terms